<DOC>
	<DOC>NCT00238953</DOC>
	<brief_summary>Clinical trial for the novo transplant recipients, which aims to assess tolerability and safety and clinical outcomes of EC-MPS in combination with cyclosporine microemulsion (CsA-ME) with or without steroids in a population of kidney transplant recipients.</brief_summary>
	<brief_title>Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria: Male and females aged 18 to 75 Recipients of cadaveric, living unrelated or living related kidney transplant, treated with CsAME, with or without corticosteroids, as primary immunosuppression Exclusion criteria: Multiorgan recipients (e.g. kidney and pancreas) or previous transplant with any organ, other than kidney. Patients with any known hypersensitivity to MPA, ECMPS or other components of the formulation (e.g. lactose). Patients with thrombocytopenia (&lt; 75,000/mm3), with an absolute neutrophil count of &lt; 1,500/mm3, and/or leukocytopenia (&lt; 2,500/mm3), and/or hemoglobin &lt; 6 g/dL at Screening or Baseline. Other inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>enteric-coated mycophenolate sodium</keyword>
</DOC>